OCUL Ocular Therapeutix

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

BEDFORD, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences in April:

24th Annual Needham Virtual Healthcare Conference

Presentation Date: Monday, April 7, 2025

Presentation Time: 3:00 PM ET

Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO

Location: Virtual

Piper Sandler Spring Biopharma Symposium

Date: Thursday, April 17, 2025

Ocular Therapeutix to host investor one-on-one meetings

Location: Boston, MA

A live webcast of the Needham presentation can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (axitinib intravitreal hydrogel, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral hydrogel or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.

Follow the Company on its website, LinkedIn, or X.

The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media

Ocular Therapeutix, Inc.

Bill Slattery

Vice President, Investor Relations



EN
31/03/2025

Underlying

OCULOcular Therapeutix

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ocular Therapeutix

 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and B...

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability Announced today that SOL-R achieved target randomization of 555 subjects Exceptional execution and retention in AXPAXLI wet AMD registrational program continue with topline data on track for SOL-1 in 1Q 2026 and SOL-R in 1H 2027 Registrational HELIOS program for AXPAXLI in NPDR expected to begin imminently using a novel primary endpoint Cash...

2h / 39m 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in S...

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a potential NDA submission for AXPAXLI in wet AMD BEDFORD, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that its SOL-R registrational trial of AXPAXLI™ (also known as OTX-TKI) in...

2h / 44m 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on ...

Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025 BEDFORD, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, November 4, 2025 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2025. Conference Call and Webcast Information: Date: Tuesday, November 4, 2025, at 8:00 AM ET Participant ...

October 28, 2025 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in October 2025. Upcoming Scientific Conferences (all times ET): American Academy of Optometry: October 8 - 11, 2025Boston, Massachusetts Poster Title: Safety and Efficacy of OTX-TKI in Moderately Severe to Severe NPDR: One Year Results from the HELIOS Ph...

October 7, 2025 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Comm...

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq: OCUL) (“Ocular”, the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced the pricing of an underwritten offering of 37,909,018 shares of its common stock at an offering price of $12.53 per share for gross proceeds of approximately $475.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. All of the sh...

September 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch